During this year's Union Budget presentation, healthcare development took centre stage as Finance Minister Nirmala Sitharaman announced an array of proposals aimed at improving medical tourism, yoga and Ayurvedic medicine exports and 'Biopharma Shakti'.

Sitharaman began presenting this year's budget by noting: "We’re inspired by three kartavyas, first is to accelerate economic growth by building resilience to global turmoil, second is to make people strong partners in prosperity, sabka saath sabka Vikas is the third kartavya."

Here is what she proposed for the improvement of healthcare services in the country:

Biopharma Shakti

The Minister started off by suggesting a ₹10,000 crore outlay for Biopharma Shakti to support domestic medication production for the next five years.

During the session, which mostly focused on the development of Tier 2 and Tier 3 cities, she stated that India’s disease burden has begun increasingly shifting towards non-communicable diseases.

To help combat this, Sitharaman said: "To develop India as a global bio-pharma manufacturing hub, I propose Bio Pharma Shakti with an outlay of ₹10,000 crores over the next 5 years. This will build an ecosystem for domestic productions of biologics and biosimilars.

"For domestic production of biologics and biosimilars, the strategy will include a biopharma-focused network with three new national institutes of pharmaceutical education and research, popularly known as NIPERS, and upgrading seven existing ones. It will also create a network of 1,000 accredited India clinical trials sites.

"We propose to strengthen the Central Drug Standard Control Organisation to meet global standards and approve timeframes through a dedicated scientific review and specialists."

By encouraging domestic production of biologics and biosimilars, the government aims to make advanced treatments more affordable and accessible for Indian patients.

The government. is yet to reveal which type of drugs will receive priority during production, whether they will be exported and whether new factories will be set up across the nation.

Speaking of how beneficial this can be for the public, Uday Deshmukh, Chairman & Founder CEO of Onco-Life Cancer Centre, exclusively told Healthandme: "This visionary initiative comes at a critical juncture, as India faces a growing burden of chronic and complex diseases such as cancer, diabetes, and autoimmune disorders.

"The proposed investment over the next five years will significantly strengthen domestic biopharmaceutical research, innovation, and manufacturing, making advanced cancer therapies more accessible and affordable.

"By accelerating clinical research and precision medicine while reducing import dependence, Biopharma Shakti has the potential to transform cancer care outcomes and build a truly self-reliant healthcare ecosystem for India.”

Import Duty Decreased On Cancer Drugs

Cancer drugs are medications, including chemotherapy, targeted therapies, and hormone therapies, used to kill cancer cells, slow growth, or relieve symptoms. Some popular medications include Cisplatin, Paclitaxel, Doxorubicin and Pembrolizumab (Keytruda), most of which are imported into India.

These imported, specialized cancer treatments, particularly targeted therapies and monoclonal antibodies, often cost thousands, placing a massive financial burden on patients, leading to lifelong debts.

However, in this year's Union Budget, Sitharaman proposed reducing import duty tax on 17 cancer drugs and seven medicines for rare diseases, which will in turn, help patients seek proper care on a timely basis.

Deshmukh commented: "India is witnessing a steady and alarming rise in cancer cases, where late detection, prolonged treatment and high medicine costs often lead to preventable complications and loss of life. Against this backdrop, the Union Budget’s decision to remove customs duty on 17 cancer drugs and 7 medicines for rare diseases stands out as a truly progressive and patient-first measure.

"Affordability remains one of the biggest hurdles in cancer care, forcing many families to delay or discontinue treatment. By reducing import duties, this move has the potential to significantly lower the cost of advanced and targeted therapies, making them accessible to a larger section of patients."

Increase In Medical Hubs And Institutions

In addition, ten new allied health disciplines will help train one lakh professionals, strengthening the healthcare support system across hospitals, wellness centres and medical tourism facilities.

Furthermore, she noted that no mental health institutions have been set up in North India and to boost care, the government will set up centres in Ranchi, Jharkhand and Tezpur, Assam.

Namrata Jain, Psychotherapist, Relationship Expert and Founder at Out Aloud commended the government's initiative to improve mental health care and told Healthandme: The focus on mental health alongside Ayurveda and wellness in this budget is a powerful affirmation that holistic wellbeing matters. Now is the time to harmonize our ancient Indian sciences with contemporary mental health frameworks to nurture resilient, compassionate communities.

"It feels deeply reassuring to see mental health, Ayurveda and wellness coming together in this budget. Healing has always been holistic and this is our reminder to blend ancient Indian wisdom with modern, trauma-informed mental health practices to support gentler, deeper, more human wellbeing."

Medical Tourism

During her ninth consecutive Union Budget, Sitharam suggested turning India into a 'global medical tourism hub' by supporting states in setting up five regional medical tourism hubs, which are expected to attract international patients, improve healthcare infrastructure and create jobs in allied services.

Pankaj Chandna, Co-Founder, Vaidam Health told this publication: "Union Budget 2026 is pushing medical value tourism from a 'hospital visit” into a full-stack, globally benchmarked care experience. The five regional medical value tourism hubs can standardise patient journeys across diagnostics, treatment, post-care and rehabilitation, while easing pressure on metros by building credible capacity in Tier 2 and Tier 3 cities.

"What stands out this year is the emphasis on technology as a growth lever, especially AI-enabled diagnostics, clinical decision support, patient coordination, and faster turnaround on care pathways, all of which directly improve international patient confidence and outcomes. The parallel focus on strengthening allied health institutions and expanding training capacity is equally important because world-class infrastructure only works when the workforce is future-ready."

Focus on Yoga And Ayurveda

Under Budget 2026-27, 1.5 lakh caregivers will be trained to provide yoga and Ayurveda-based services to improve access to wellness care while also creating large-scale employment opportunities. The proposal reflects the growing demand for traditional and preventive healthcare in India and abroad.

She also proposed setting up new All India Institutes of Ayurveda as part of the government’s push to expand traditional and modern healthcare infrastructure as well as to improve the quality of Ayurveda education and help standardise treatment practices across the country.

"I propose to set up three new All India Institutes of Ayurveda; Upgrade AYUSH pharmacies and drug testing labs and make available more skilled persons; Upgrade the WHO Global Traditional Medicine Centre in Jamnagar," said Sitharaman.

Focusing on the connection between traditional Indian medicine and medical tourism, Sonam Garg Sharma, Founder, Medical Linkers told Healthandme: "As a country, we are increasingly recognised for combining clinical excellence with value-driven care, and healthcare hubs that integrate advanced diagnostics, post-treatment rehabilitation, and AYUSH-led wellness therapies such as yoga and Ayurveda can take that advantage further by offering a truly end-to-end patient journey.

"This also adds meaningful momentum to India’s medical value tourism story, where outcomes, experience, and continuity of care matter as much as affordability."

Upgrade In Geriatric And Professional Care

Lastly, Sitharaman added that institutions for allied health professionals will be upgraded and professionals will be trained in the coming year to cover geriatric and allied sectors. New AHP institutes will also be set up in the private and government sectors

Cancer, a rare occurrence? Unfortunately, not anymore. According to recent findings from an analysis published in The Lancet, cancer is one of the top 10 causes of death among Indian children. This is an alarming statistic, signalling an under-recognised public health problem. Data in the Global Burden of Disease Study 2023 noted that even as infectious diseases decline, noncommunicable diseases like cancer are emerging as a serious threat to child survival and well-being. In India, this epidemiological shift is particularly concerning in the context of childhood cancers. Despite being rare, they are highly treatable when detected in the early stages—yet most cases are diagnosed late.

As per the Indian Council of Medical Research’s National Centre for Disease Informatics and Research (ICMR-NCDIR), childhood cancers accounted for 3–5 per cent of cancer cases reported in India in 2022. The country sees an estimated 50,000 to 60,000 cases every year among children aged 0–14 years. This makes it one of the highest burdens globally. In 2023, 377,000 cases of childhood cancer were reported globally, along with 144,000 deaths, according to The Lancet research paper.

Read more: 3 Children In Every 4 Minutes Are Diagnosed With Cancer, That's What Makes Awareness Important Says Doctor

Hidden cancer burden in India

When it comes to childhood cancers in India, leukaemia, or blood cancers, are the most common, followed by lymphomas and tumours of the central nervous system. Collectively, these categories comprise most cases of childhood cancers in the country. The statistics vary across regions, with Delhi reporting the highest number of cases due to better diagnostic facilities. However, experts believe that the actual burden is likely to be much higher. Incomplete cancer registration and limited access to proper diagnostic facilities in underserved and rural areas are to blame for delayed diagnosis.

Why is childhood cancer detected late in India?

Experts say that cancer deaths in India can largely be attributed to delayed diagnosis. Early symptoms of cancer in children include fatigue, fever, unexplained weight loss, and swelling in certain body parts. These symptoms are often overlooked, leading to delays at multiple levels. According to the ICMR 2022 factsheet, a significant proportion of children reach hospitals only at advanced stages of the disease. By then, treatment becomes more complex, more expensive, and less likely to succeed.

Access to cancer care for children

Access to cancer care for children is uneven in India. Paediatric oncology services are largely limited to hospitals in tier-one cities, forcing families from rural areas and smaller towns to travel in order to access proper treatment. This imbalance results in delayed care, especially for economically vulnerable families. Financial limitations are another barrier in the process—even if treatment costs are subsidised, expenses such as travel, accommodation, and loss of income can be overwhelming.

Read more: 41 million children aged 5-19 living with high BMI in India: Study

Irregular survival patterns

Globally, survival rates for childhood cancers exceed 80 per cent in high-income countries. In India, outcomes are uneven. The ICMR 2022 factsheet noted that survival depends on the stage of diagnosis, type of cancer, and where the child is treated. Hospitals in India are reporting improving survival rates for certain forms of cancer, such as acute lymphoblastic leukaemia. The ICMR factsheet also highlights the need for a dedicated approach to paediatric cancer care, including better infrastructure, trained doctors, and stronger referral systems.

Indian weddings are a global sensation for all the taam-jhaam—the outfits, the music, the madness, and the unmatched vibe. In an ever-evolving culture, several new trends become a part of the wedding buzz in India. At a time when weight-loss drugs are the talk of the town, it is no surprise that they, too, have joined the list of new must-haves for Indian brides. For many soon-to-be brides and grooms, the pressure to look a class apart is always high. Amid the madness of wedding preparations, brides and grooms often miss the gym—weight-loss drugs come to their rescue.

India's Mounjaro brides

Clinics in metropolitan cities like Delhi and Mumbai are introducing weight-loss treatments into their traditional pre-bridal and bridal packages. Bridal packages initially focused on hair care, skincare, hair styling, and grooming—but they have now expanded to include shots of Mounjaro, a popular weight-loss drug. Some wellness centres in the city have advertised that they offer customised programmes combining workout routines, nutrition, and medication to help clients achieve desired results.

Doctors have noticed a clear rise in such inquiries. Several specialists report that a significant portion of their patients seeking obesity treatments are engaged couples working within a fixed timeline. While medical professionals acknowledge this demand, many emphasise that such treatments should only be prescribed when medically appropriate, rather than purely for cosmetic reasons.

Read more: India To Strictly Inspect GLP-1 Drugs To Curb Misuse: Govt Flags Risks Amid Weight-loss Hype

The pressures of looking good at a wedding

Weddings in India are deeply rooted in tradition, elaborate, and often burdened by societal expectations around appearance. As a result, many resort to glycolic treatments, injections of Mounjaro, and sometimes even facial procedures for a bridal glow. However, weight-loss drugs serve a different purpose—they can boost a bride's confidence by helping her feel more comfortable in her own skin.

Others share similar experiences. Some individuals admitted that concerns about body image, often influenced by family expectations or societal standards, played a major role in their decision. In certain cases, weight became a factor in arranged marriage discussions, pushing individuals to seek faster solutions. However, most discontinued the injections shortly after their weddings.

Why are weight-loss drugs becoming so popular?

According to experts, the growing popularity of weight-loss drugs is linked to their increased availability. Globally, pharmaceutical companies have introduced their own versions of obesity treatments in India, and demand has risen drastically. At the same time, more affordable alternatives are being introduced by manufacturers to make these drugs accessible to a wider audience.

A word of caution

Despite the surge, experts warrant caution. Weight-loss drugs are intended to help clinically obese or significantly overweight individuals, as well as patients with type 2 diabetes and hypertension. These drugs are not meant to act as quick fixes for short-term aesthetic goals. Experts, therefore, stress the importance of using these drugs under expert guidance and supervision.

Misuse of weight-loss drugs

Doctors are also concerned about the misuse of weight-loss drugs—health authorities have started monitoring the sale and promotion of such medication, especially the cheaper versions on the market. Experts say that relying solely on these drugs instead of making essential lifestyle changes may not lead to sustainable results. For many, the appeal lies in convenience—maximum benefits with minimal effort. While these drugs may fit into a hectic routine, doctors continue to emphasise the need for a balanced approach to weight loss.

The UK National Health Service (NHS) is soon expected to roll out free weight-loss Wegovy jab to over a million people in England at risk of heart attacks and strokes.

The move is based on the recommendation of the National Institute for Health and Care Excellence (NICE), which said that overweight people with heart problems, or serious circulation problems in their legs, should have the weekly jab "as an extra layer of protection".

Developed by Danish drugmaker Novo Nordisk, Wegovy is primarily an antidiabetic medication used to treat Type 2 diabetes. People receiving the weight-loss drug Wegovy sustained weight loss for up to four years.

"We know that people who have already had a heart attack or stroke are living with real fear that it could happen again. The evidence from the clinical trial is compelling. It showed that people taking semaglutide alongside their existing heart medicines were significantly less likely to have another heart attack or stroke,” said Helen Knight, from NICE.

"Today's decision gives thousands of people in that situation an extra layer of protection, on top of the medicines they are already taking," she added.

Also read: Foundayo: US FDA Approves Eli Lilly’s GLP-1 Weight Loss Pill

Wegovy and Heart Risk

A November 2023 study, published in the New England Journal of Medicine, elicited a randomized clinical trial of tens of thousands of people, in which Wegovy - alongside existing heart medicines - was linked to a 20% reduced risk of heart attacks and strokes.

Importantly, benefits were seen early in the clinical trial, before significant weight loss occurred, suggesting the drug works directly on the heart and blood vessels, not just through weight loss, as per the NICE

The BBC reported that the UK faces a significant heart disease burden, and every year:

100,000 people get hospitalized due to heart attacks,

100,000 people experience a stroke

350,000 people live with peripheral arterial disease.

Sharon Hodgson, the health minister, said weight-loss drugs were a “gamechanger” and giving them to people at risk of heart attacks and strokes would be a “lifesaver”.

Also read: India To Strictly Inspect GLP-1 Drugs To Curb Misuse: Govt Flags Risks Amid Weight-loss Hype

Wegovy Is Top Weight-Loss Choice for US Teens

Only Wegovy has been approved by the US FDA for children aged 12 and older who are living with obesity. Since the approval in late 2022, the prescriptions have surged.

According to health data company Truveta, which reviewed medical records from 30 US health systems, prescriptions for Wegovy among teens jumped by 50 percent in 2024—rising from 9.9 per 100,000 adolescents in 2023 to 14.8 per 100,000 in 2024.

The first quarter of 2025 showed another increase, with the rate reaching 17.3 per 100,000.